Community Trust & Investment Co. Sells 2,570 Shares of Johnson & Johnson (NYSE:JNJ)

Community Trust & Investment Co. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 113,969 shares of the company’s stock after selling 2,570 shares during the quarter. Johnson & Johnson makes up 1.8% of Community Trust & Investment Co.’s investment portfolio, making the stock its 25th biggest holding. Community Trust & Investment Co.’s holdings in Johnson & Johnson were worth $14,746,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after buying an additional 1,627,370 shares during the last quarter. Phocas Financial Corp. increased its stake in Johnson & Johnson by 999,928.6% in the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $174,342,000 after buying an additional 125,161,066 shares during the last quarter. Northern Trust Corp increased its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock valued at $4,910,381,000 after buying an additional 313,073 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Johnson & Johnson by 11.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after buying an additional 2,204,757 shares during the last quarter. Finally, Morgan Stanley increased its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock valued at $2,784,913,000 after buying an additional 122,033 shares during the last quarter. 72.01% of the stock is currently owned by institutional investors.

JNJ traded up $3.26 on Friday, hitting $132.32. The company’s stock had a trading volume of 2,314,007 shares, compared to its average volume of 6,702,304. The company’s 50 day simple moving average is $129.92 and its 200-day simple moving average is $135.00. The firm has a market cap of $347.95 billion, a P/E ratio of 16.18, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the firm earned $2.10 EPS. Equities analysts predict that Johnson & Johnson will post 8.59 earnings per share for the current fiscal year.

Several research firms have commented on JNJ. Raymond James decreased their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Barclays began coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research report on Thursday, July 18th. Finally, Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $151.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is a trade deficit?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.